• Home >
  • Publications >
  • Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial

Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial

1 Sept 2021European Journal of Cancer

DOI : 10.1016/j.ejca.2021.05.037

Authors

Banu K. Arun, Hyo S. Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L. Puhalla, Katherine M. Bell-McGuinn, Bruce A. Bach, Madan G. Kundu, Christine K. Ratajczak, David Maag, Véronique Diéras